News & Insights

Keep upto date with all the latest news and insights from Nanopharm.

  • Nanopharm Announce Appointment of Head of Device Development

    Device Development Established at Nanopharm Ltd

    Read More
  • Nanopharm Announces Appointment of Chairman

    Nanopharm Announces the Appointment of Mark Clement as Chairman of the Board

    Read More
  • Addition of the Malvern G3-ID at Nanopharm

    Demonstrating bioequivalence (BE) for complex generics such as nasal spray suspension drug products is a challenging task. Sponsors not only have to consider device requirements but also understand the properties of the API in the presence of functional excipients.

    Read More
  • New research into in vitro strategies for demonstrating bioequivalence in generic nasal sprays

    Nanopharm Ltd, supported by Malvern instruments and with funding from the Food and Drug Administration (FDA), have carried out experimental studies to identify analytical strategies that can help bring generic nasal sprays to market faster.

    Read More
  • Nanopharm Ltd launches dissolution testing service for orally inhaled drug products utilising its proprietary UniDose™ technology

    Nanopharm Ltd, a leading provider of tailored analytical and product development for orally inhaled and nasal drug products (OINDPs), today announced the availability of dissolution testing services utilising the company’s proprietary UniDose™ aerosol collection apparatus.

    Read More
  • Nanopharm attended CPHI 2015, Madrid

    Nanopharm attended CPHI 2015 in sunny Madrid. Great to meet up with new and existing clients.

    Read More
  • New Web Site Launch

    Read More
  • One Year Anniversary

    July 2015: Nanopharm’s 1st year anniversary at Cavendish House

    Read More